Air Industries Group (AIRI) - Q3 2025 Filing Summary
Business Context and Reporting Period
Air Industries Group (AIRI) is a manufacturer of precision components and assemblies for aerospace and defense contractors. This Form 10-Q covers the quarterly period ended September 30, 2025. The company operates as a single segment, with significant exposure to U.S. military aviation and commercial aviation programs. As of November 12, 2025, there were 4,775,777 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Sales | $10.31 million | $12.56 million | $35.11 million | $40.19 million |
| Gross Profit | $2.30 million | $1.94 million | $6.36 million | $6.49 million |
| Gross Margin | 22.3% | 15.5% | 18.1% | 16.2% |
| Operating Income (Loss) | $0.32 million | $0.07 million | $(0.42) million | $0.56 million |
| Net Loss | $(0.04) million | $(0.40) million | $(1.45) million | $(0.81) million |
| EPS (Basic & Diluted) | $(0.01) | $(0.12) | $(0.36) | $(0.24) |
Liquidity, Debt, and Cash Flow
- Cash Position: Cash and cash equivalents were $126,000 as of September 30, 2025, down from $753,000 at year-end 2024. However, the company holds $3.93 million in restricted cash (pledged as security for its credit facility), bringing total cash and restricted cash to $4.06 million.
- Debt Obligations: Total debt outstanding is approximately $28.65 million. This includes $21.96 million under the Current Credit Facility (Webster Bank) and $4.87 million in Related Party Subordinated Notes.
- Working Capital: Working capital decreased to $4.32 million from $11.78 million in the prior year, primarily due to increased debt and inventory levels.
- Cash Flow: Operating activities used $0.75 million in cash for the nine months ended September 30, 2025, compared to generating $0.51 million in the prior year period. Investing activities used $2.82 million for capital expenditures. Financing activities provided $6.88 million, driven by debt drawdowns and equity sales.
Material Changes and Operational Highlights
- Revenue Decline: Net sales decreased 17.9% in Q3 and 12.6% YTD compared to 2024, attributed to timing and product mix changes. Military sales decreased significantly, while commercial sales increased.
- Margin Improvement: Despite lower sales, gross margins improved to 22.3% in Q3 (from 15.5% in Q3 2024) due to product mix shifts and cost reduction initiatives.
- Inventory Build: Inventory increased to $34.43 million from $28.81 million at year-end 2024, reflecting preparation for future orders and extended lead times for raw materials.
- Backlog: Total unfilled contract value is $269.0 million, including $131.8 million in firm backlog. Revenue acceleration is expected to be delayed until early 2026 due to manufacturing complexity and supply chain lead times.
- Cost Reductions: Management initiated workforce reductions in Q3 to align operating expenses with production volumes.
Outlook, Risks, and Contingencies
- Going Concern Warning: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern for the next twelve months. This is due to the maturity of the Current Credit Facility on December 30, 2025, and Related Party Notes on July 1, 2026, combined with existing covenant defaults.
- Covenant Defaults: The company is in default of a Fixed Charge Coverage Ratio (FCCR) requirement for the period ended June 30, 2025 (achieved 0.76x vs. required 1.05x) and exceeded capital expenditure limits. While compliant with the 1.25x FCCR for the period ended September 30, 2025, waivers have not been obtained for prior defaults.
- Refinancing Status: The company is in constructive discussions with lenders regarding refinancing or extensions. Approximately $3.93 million of recent ATM offering proceeds are restricted as additional security for the lender.
- Equity Raising: The company has temporarily paused equity raising activities while evaluating its capital structure.
- Legal Contingency: An ongoing lawsuit with Contract Pharmacal Corp. regarding a sublease dispute remains pending at the Appellate Division level, with damages sought reduced to $700,000.
- Internal Controls: The company disclosed a material weakness in internal controls over financial reporting related to IT systems, which remains unremediated as of September 30, 2025.
Investor Verification Checklist
- Debt Maturity: Verify the status of refinancing negotiations for the $22 million Current Credit Facility maturing December 30, 2025.
- Covenant Waivers: Confirm if waivers have been obtained for the FCCR default recorded in Q2 2025 and the capital expenditure limit breach.
- Restricted Cash: Assess the liquidity impact of the $3.93 million restricted cash balance and the company's ability to access it if the lender exercises remedies.
- Backlog Conversion: Monitor the timeline for converting the $269 million unfilled contract value into revenue, noting the management guidance of delays until early 2026.
- Going Concern: Review subsequent filings for updates on the "substantial doubt" regarding the company's ability to continue operations.